Nucleic acids encoding antigens associated with polymyositis and dermatomositis

• US 6,160,107 A
• Filed: 11/10/1992
• Issued: 12/12/2000
• Est. Priority Date: 09/07/1990
• Status: Expired due to Fees

• Current Assignee: Oklahoma Medical Research Foundation, The Board of Regents of the University of Colorado (University of Colorado System)
• Original Assignee: Oklahoma Medical Research Foundation, The Board of Regents of the University of Colorado (University of Colorado System)
• Inventors: Ge, Qun, Targoff, Ira N.
• Primary Examiner(s): Sisson, Bradley L.
• Application Number:
  US07/975,902
• Time in Patent Office: 2,954 Days
• Field of Search: 435/6, 536/23.5, 536/24.31, 536/23.4
• US Class Current: 536/23.5
• CPC Class Codes: C07K 14/4713 Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: Y10T 436/143333 Saccharide [e.g., DNA, etc.]

Abstract

Proteins including at least one epitope of the Mi-2 antigen, which are used for the diagnosis of dermatomyositis, and proteins including at least one epitope of the PM-Scl antigen, which are used for the diagnosis of polymyositis, particularly polymyositis-scleroderma overlap disorders are provided in an easily purified form for use in immunoassays and purification of the associated autoantigens. DNA that encode these proteins and that may also be used in diagnostic assays or as probes to obtain related DNA are also provided.

Claims

1. An isolated nucleic acid molecule, consisting essentially of the sequence shown in FIG. 1 that encodes all or a peptide portion of an Mi-2 protein, wherein the protein expressed from said nucleic acid molecule includes at least one epitope of said protein that is bound by a myositis-specific autoantibody.

2. The nucleic acid molecule of claim 1, labelled for use as a probe, wherein said probe hybridizes to a nucleic acid sequence that encodes an Mi-2 antigen.

3. An isolated nucleic acid molecule, consisting essentially of twenty-four consecutive nucleotides of the sequence shown in a sequence selected from the group consisting of the sequences shown in FIG. 2A, FIG. 2B, FIG. 4A, FIG. 4B, FIG. 4C, FIG. 4D and FIG. 4E, that encodes all or a peptide portion of a myositis specific PM-Scl protein, wherein the protein expressed from said sequence includes at least one epitope of PM-Scl that is bound by a myositis-specific autoantibody.

4. The nucleic acid molecule of claim 3 labelled for use as a probe, wherein said probe hybridizes to a nucleic acid sequence that encodes a PM-Scl antigen.

5. A nucleic acid molecule for use as a probe consisting essentially of a sequence of at least 10 nucleotides of the sequence shown in FIG. 1, wherein the molecule specifically hybridizes under non-stringent conditions to a nucleic acid molecule that encodes an Mi-2 antigen.

6. The nucleic acid molecule of claim 5, labelled with a detectable label.

7. A nucleic acid molecule for use as a probe consisting essentially of a sequence of at least 10 nucleotides of a sequence selected from the group consisting of the sequences shown in FIG. 2A, FIG. 2B, FIG. 4A, FIG. 4B, FIG. 4C, FIG. 4D and FIG. 4E, wherein the molecule specifically hybridizes under non-stringent conditions to a nucleic acid molecule that encodes a PM-Scl antigen.

8. The nucleic acid molecule of claim 7 labelled with a detectable label.